Filtered By:
Condition: Pain
Countries: Canada Health

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 30 results found since Jan 2013.

End-of-Life Care for Stroke
Stroke is a leading cause of disability and the third leading cause of death in Canada, according to the Heart and Stroke Association. Despite a high mortality rate, the experience of dying from a stroke has received limited attention from a palliative point of view. When attempting to make inferences from other specialties that have well researched methods of palliation, there was an obvious gap when considering the stroke population. Palliative stroke patients, at the Royal University Hospital, rarely have access to a bed on a specialized palliative care unit.
Source: Journal of Pain and Symptom Management - November 30, 2018 Category: Palliative Care Authors: Shelley Jolly, Ruth Whelan, Kimberly Davy Source Type: research

Estimating the Threshold Value for Change for the Six Dimensions of the Impairment Inventory of the Chedoke-McMaster Stroke Assessment.
Conclusions: Clinicians can use a change of 1 impairment point for the arm, hand, leg, foot, and postural control dimensions and a change of 2 impairment points for the shoulder pain dimension to identify true change in a patient's motor recovery. PMID: 31040505 [PubMed]
Source: Physiotherapy Canada - May 3, 2019 Category: Physiotherapy Authors: Beyer R, Wharin C, Gillespie E, Odumeru K, Stratford PW, Miller PA Tags: Physiother Can Source Type: research

New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

International consensus recommendations for outcome measurement in poststroke arm rehabilitation trials.
CONCLUSIONS: The SMART Toolbox provides a refined selection of measures that capture outcomes considered important by stakeholders for each ICF domain. CLINICAL REHABILITATION IMPACT: The toolbox will facilitate data aggregation for efficacy analyses thereby strengthening evidence to inform clinical practice. Clinicians can also use the toolbox to guide selection of measures ensuring a patient-centred focus. PMID: 33215905 [PubMed - as supplied by publisher]
Source: European Journal of Physical and Rehabilitation Medicine - November 20, 2020 Category: Rehabilitation Authors: Duncan Millar J, van Wijck F, Pollock A, Ali M Tags: Eur J Phys Rehabil Med Source Type: research

Sex Differences in Care Need and Survival in Patients Admitted to Nursing Home Poststroke.
CONCLUSIONS: Despite lower subsequent mortality, women admitted to nursing home after stroke required more care than men. Pain and depression are two treatable symptoms that disproportionately affect women. PMID: 31987059 [PubMed - as supplied by publisher]
Source: The Canadian Journal of Neurological Sciences - January 27, 2020 Category: Neurology Authors: Yu AYX, Maclagan LC, Diong C, Austin PC, Kapral MK, Swartz RH, Bronskill SE Tags: Can J Neurol Sci Source Type: research

Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis at Low Surgical Risk: A Health Technology Assessment.
Conclusions: Both TAVI (transfemoral route) and SAVR resulted in improved patient symptoms and quality of life during the 1 year of follow-up. The TAVI procedure is less invasive and resulted in greater symptom improvement and quality of life than SAVR 30 days after surgery. The TAVI procedure also resulted in a small improvement in mortality and disabling stroke at 30 days. At 1 year, TAVI and SAVR were similar with regard to mortality, although TAVI may result in a slightly lower risk of disabling stroke. According to the study authors, longer follow-up is needed to better understand how long TAVI valves last and to draw...
Source: Ontario Health Technology Assessment Series - November 27, 2020 Category: General Medicine Tags: Ont Health Technol Assess Ser Source Type: research

Temporal Summation in Chronic Pelvic Pain.
CONCLUSION: Women with chronic pelvic pain and allodynia show significant worsening of pain with successive strokes of a cotton-tip applicator, thus indicates that wind-up and central sensitization are present in women with chronic pelvic pain and allodynia. Identification of summation is further evidence of neuroplasticity, which is helpful in innovative therapies for chronic pelvic pain. PMID: 31882288 [PubMed - as supplied by publisher]
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - December 30, 2019 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research

Association of Preoperative Medical Consultation With Reduction in Adverse Postoperative Outcomes and Use of Processes of Care Among Residents of Ontario, Canada
CONCLUSIONS AND RELEVANCE: In this cohort study, preoperative medical consultation was not associated with a reduction but rather with an increase in adverse postoperative outcomes, suggesting a need for further refinement of target populations, processes, and interventions related to preoperative medical consultation. These findings highlight the need for further research and suggest that referral for preoperative medical consultation and subsequent testing should be carefully guided by individual-level consideration of risks and benefits.PMID:36972037 | DOI:10.1001/jamainternmed.2023.0325
Source: Pain Physician - March 27, 2023 Category: Anesthesiology Authors: Weiwei Beckerleg Daniel Kobewka Duminda N Wijeysundera Manish M Sood Daniel I McIsaac Source Type: research

Neuromuscular Electrical Stimulation for Treatment of Muscle Impairment: Critical Review and Recommendations for Clinical Practice.
Conclusion: This article provides physiotherapists with a resource to enable evidence-informed, effective use of NMES for PT practice. PMID: 29162949 [PubMed - in process]
Source: Physiotherapy Canada - November 24, 2017 Category: Physiotherapy Authors: Nussbaum EL, Houghton P, Anthony J, Rennie S, Shay BL, Hoens AM Tags: Physiother Can Source Type: research

“In this together”: Social identification predicts health outcomes (via self-efficacy) in a chronic disease self-management program
Conclusion The results are consistent with growing evidence of the value of a social identity-based approach in various health and clinical settings. The success of chronic disease self-management programs could be enhanced by attending to and augmenting group identification during and after the program.
Source: Social Science and Medicine - March 5, 2018 Category: Psychiatry & Psychology Source Type: research

A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention
ConclusionWe found that a strategy favoring patients staying on statin therapy is cost effective even if patients maintained on statin are at risk of rhabdomyolysis. Our results are explained by the fact that statins are highly effective in reducing the CV risk in patients at high CV risk, and this benefit largely outweighs the risk of rhabdomyolysis.
Source: Molecular Diagnosis and Therapy - April 12, 2018 Category: Molecular Biology Source Type: research

Bioness launches StimRouter neuromod system in Canada
Rehabilitation device maker Bioness today touted the launch of its StimRouter neuromodulation system in Canada, and said that the system had been implanted in its first procedures in the region. The first implantations of the device were performed at Toronto’s Women’s College Hospital, the Valencia, Calif.-based company said. “Significant advances in the miniaturization and durability of neuromodulation devices have provided interventional pain physicians with the right tools, like the StimRouter PNS System, to treat chronic pain related to nerve injuries, trauma, stroke and other irreversible damages wi...
Source: Mass Device - June 11, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Neuromodulation/Neurostimulation Bioness Source Type: news

Long-Term Outcomes in the Management of Central Neuropathic Pain Syndromes: A Prospective Observational Cohort Study.
CONCLUSION: Patients with central neuropathic pain syndromes managed in tertiary care centers were less likely to achieve a meaningful improvement in pain and function compared with patients with peripheral neuropathic pain at 12-month follow-up. PMID: 29996953 [PubMed - as supplied by publisher]
Source: The Canadian Journal of Neurological Sciences - July 12, 2018 Category: Neurology Authors: Staudt MD, Clark AJ, Gordon AS, Lynch ME, Morley-Forster PK, Nathan H, Smyth C, Stitt LW, Toth C, Ware MA, Moulin DE Tags: Can J Neurol Sci Source Type: research